SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into an exclusive licensing agreement with ASK Pharm for its proprietary pan-RAS (ON) inhibitor AN9025. Under the terms of the agreement, ASK Pharm will obtain exclusive rights to develop, manufacture, and commercialize ...

Core Viewpoint - Innovent Biologics has successfully included seven innovative products in the updated 2025 National Reimbursement Drug List (NRDL), enhancing patient access to critical therapies for major diseases in China [1][2]. Product Summaries - **TYVYT® (sintilimab injection)**: Newly included indication for advanced endometrial cancer in combination with fruquintinib, addressing a significant treatment gap for patients with limited responses to traditional therapies [4][3]. - **SYCUME® (teprotumumab N01 injection)**: First approved IGF-1R antibody drug in China, newly listed for moderate-to-severe thyroid eye disease, significantly improving patient accessibility and affordability [6][5]. - **Limertinib**: Newly listed for treating advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC) and as a first-line treatment for specific EGFR mutations, offering enhanced penetration across the blood-brain barrier [9][8]. - **Dupert® (fulzerasib)**: Newly listed for advanced NSCLC patients with KRAS G12C mutation, providing a novel targeted therapy option [10]. - **DOVBLERON® (taletrectinib)**: Newly listed for locally advanced or metastatic ROS1-positive NSCLC, potentially offering a best-in-class therapy [12][11]. - **Retsevmo® (selpercatinib)**: Newly listed for various indications in NSCLC and thyroid cancer, being the first RET inhibitor approved globally [14][13]. - **Jaypirca® (pirtobrutinib)**: Newly listed for relapsed or refractory mantle cell lymphoma, addressing unmet needs for heavily treated patients [16][15]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing affordable, high-quality medicines for oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases [17]. The company has launched 17 products and has multiple assets in various stages of clinical trials [17].

Core Viewpoint - Innovent Biologics reported strong interim results for 2025, showcasing significant revenue growth and profitability improvements driven by its dual-engine growth model and global innovation strategy [2][4]. Financial Performance - Total revenue reached RMB 5.95 billion, marking a 50.6% year-on-year increase - Product revenue was RMB 5.23 billion, up 37.3% year-on-year - Net profit stood at RMB 1.21 billion, with EBITDA at RMB 1.41 billion - Gross margin improved to 86.8%, an increase of 2.7 percentage points year-on-year - Selling and administrative expenses ratio decreased to 44.2%, down 7.9 percentage points year-on-year - R&D investment totaled RMB 903 million - Cash on hand was approximately USD 2 billion [9]. Product Portfolio Expansion - The product portfolio expanded to 16 drugs, including three new oncology launches: Dovbleron® (taletrectinib), Limertinib, and Jaypirca® (pirtobrutinib) - Strengthened general biomedicine portfolio with innovative pipeline products such as SINTBILO® (tafolecimab injection) and SYCUME® (teprotumumab N01 injection) [9][10]. Innovation and Pipeline Development - Several core pipeline candidates achieved key proof-of-concept data and are entering global registration trials, indicating strong innovation capabilities - The company aims to advance five pipeline programs into global Phase 3 trials by 2030 [3][4][11]. Strategic Goals and Future Outlook - Innovent aims to achieve RMB 20 billion in product revenue by 2027 - The company plans to consolidate its leadership in oncology and explore diversified commercialization strategies [4][8]. Globalization and Market Access - Innovent is enhancing its global presence with broader market access and prioritizing novel pipeline's global R&D - The company has established a lifecycle management system to enhance brand strength [14][10]. Commitment to ESG and Philanthropy - Innovent is committed to responsible business practices and enhancing ESG management - The company has supported over 200,000 patients through dedicated patient assistance programs, with drug donations totaling RMB 3.6 billion [15][20].

Core Insights - Innovent achieved historic milestones in 2024, with Non-IFRS net profit of RMB 331.6 million and Non-IFRS EBITDA of RMB 411.6 million, marking the first positive results in these metrics [5] - Total revenue reached RMB 9,421.9 million, a year-over-year growth of 51.8%, with product sales revenue growing by 43.6% to RMB 8,227.9 million [5] - The company aims for RMB 20 billion in product revenue by 2027 and plans to advance five pipeline assets to global MRCT Phase 3 by 2030 [2][9] Financial Performance - Non-IFRS profit and EBITDA turned positive for the first time, indicating improved financial health [5] - Gross profit margin increased to 84.9%, up by 2.1 percentage points year-over-year [5] - Selling, General and Administrative (S,G&A) expenses ratio decreased to 50.9%, down by 7.1 percentage points year-over-year [5] Product Development and Pipeline - Innovent expanded its product portfolio to 15 approved products and plans six new product launches in 2025 [5][9] - Key pipeline assets include Dovbleron®, Limertinib, and Jaypirca®, targeting oncology and chronic diseases [5] - The company is advancing multiple next-generation programs in oncology and autoimmune diseases, with promising Phase 1 results reported [9] Strategic Goals and Partnerships - Innovent is focused on becoming a premier global biopharmaceutical company, emphasizing sustainable growth and innovation [2][9] - The company has established partnerships with over 30 global healthcare companies, enhancing its research and development capabilities [10] - Innovent's commitment to ESG practices is reflected in its 'AAA' rating in MSCI ESG rankings and various community support initiatives [9][10]